| Code | CSB-RA011661MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Manfidokimab, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a component of receptor complexes for both IL-4 and IL-13, two cytokines central to type 2 inflammatory responses. Upon ligand binding, IL4R initiates signaling cascades that promote IgE class switching, mucus production, and recruitment of eosinophils. Dysregulated IL4R signaling plays a critical role in allergic diseases, atopic dermatitis, asthma, and certain fibrotic conditions, making it an important therapeutic target for type 2 inflammation-driven disorders.
Manfidokimab is a clinical-stage therapeutic antibody that blocks IL-4 and IL-13 signaling by binding to IL4R alpha, preventing downstream inflammatory cascades. This biosimilar provides researchers with a valuable tool for investigating IL4R-mediated pathways, studying type 2 immune responses, and exploring mechanisms of allergic and inflammatory diseases. It supports studies in immunology, dermatology, and respiratory research where IL4R modulation is of interest.
There are currently no reviews for this product.